Business Description
Taho Pharmaceuticals Ltd
ISIN : TW0006467004
Total Employee Number:
28Description
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 35 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 191.01 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.7 | |||||
3-Year EBITDA Growth Rate | -20 | |||||
3-Year EPS without NRI Growth Rate | -16.7 | |||||
3-Year FCF Growth Rate | -15.6 | |||||
3-Year Book Growth Rate | 34.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.2 | |||||
9-Day RSI | 82.76 | |||||
14-Day RSI | 79.41 | |||||
3-1 Month Momentum % | -5.74 | |||||
6-1 Month Momentum % | -11.54 | |||||
12-1 Month Momentum % | -40.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.3 | |||||
Quick Ratio | 18.3 | |||||
Cash Ratio | 18.07 | |||||
Days Sales Outstanding | 97.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.49 | |||||
Operating Margin % | -12244.62 | |||||
Net Margin % | -12031.45 | |||||
EBITDA Margin % | -11561.64 | |||||
FCF Margin % | -10351.03 | |||||
OCF Margin % | -10099.7 | |||||
ROE % | -58.88 | |||||
ROA % | -55.61 | |||||
ROIC % | -362.67 | |||||
3-Year ROIIC % | 35.29 | |||||
ROC (Joel Greenblatt) % | -1011.76 | |||||
ROCE % | -57.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 5.83 | |||||
PS Ratio | 5131.58 | |||||
PB Ratio | 29.64 | |||||
Price-to-Tangible-Book | 29.68 | |||||
EV-to-EBIT | -41.73 | |||||
EV-to-EBITDA | -43.35 | |||||
EV-to-Revenue | 5011.85 | |||||
EV-to-FCF | -48.42 | |||||
| Price-to-Net-Current-Asset-Value | 35.98 | |||||
| Price-to-Net-Cash | 36.45 | |||||
Earnings Yield (Greenblatt) % | -2.4 | |||||
FCF Yield % | -2.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Taho Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1.981 | ||
| EPS (TTM) (NT$) | -4.592 | ||
| Beta | 4.9061 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 24.91 | ||
| Volatility % | 66.61 | ||
| 14-Day RSI | 79.41 | ||
| 14-Day ATR (NT$) | 12.230849 | ||
| 20-Day SMA (NT$) | 143 | ||
| 12-1 Month Momentum % | -40.05 | ||
| 52-Week Range (NT$) | 100.5 - 205.5 | ||
| Shares Outstanding (Mil) | 52.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Taho Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Taho Pharmaceuticals Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Taho Pharmaceuticals Ltd Frequently Asked Questions
What is Taho Pharmaceuticals Ltd(ROCO:6467)'s stock price today?
The current price of ROCO:6467 is NT$195.00. The 52 week high of ROCO:6467 is NT$205.50 and 52 week low is NT$100.50.
When is next earnings date of Taho Pharmaceuticals Ltd(ROCO:6467)?
The next earnings date of Taho Pharmaceuticals Ltd(ROCO:6467) is .
Does Taho Pharmaceuticals Ltd(ROCO:6467) pay dividends? If so, how much?
Taho Pharmaceuticals Ltd(ROCO:6467) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Taho Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers